Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

Despite a rocky start for many drugmakers at the start of last year, 2024’s fourth quarter saw just two of the top 25 global ...

Eli Lilly just scored a major win with its Phase 3 BRAVE-AA-PEDS study. The trial confirmed baricitinib's effectiveness in ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Discover 25 top investment-grade stocks to buy! See strategies to capitalize on market volatility and build a portfolio to ...

DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the evolving Metabolic Dysfunction-Associated Steatohepatitis (MASH) market ...

H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.

Recent developments at Eli Lilly (NYSE:LLY) have highlighted significant strides in both product innovation and operational ...

NKTR fourth-quarter earnings and revenues lag estimates. 2025 is poised to be a catalyst year for rezpeg, with multiple data readouts expected. Stock rises.

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Axiomer ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expect ...